Pricing

Outlook Therapeutics

0 followers

‌

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO.

Industries

Headquarters

Woodbridge Township, United States

Employees

Links

Org chart

C. Russell Trenary III

President & CEO

C. Russell Trenary III

Collapse

COO

Lawrence A. Kenyon

CFO

Chief Commercial Officer

Associate Director, Bioassay Development

Entisar Dahan, MPM, PHR

Director Human Resources

Jennifer Kissner

Senior Vice President, Clinical & Regulatory Affairs

Kathleen Billman

Executive Director, Clinical Affairs

Executive Director, Patient Access & Marketing

Christoph Puetz

Head Of Information Technology Department

Surendra Sharma

Senior Vice President, Medical Affairs

Executive Director of Physician Relations

Teams

Directors

12 members

Operations Team

6 members

Leadership Team

4 members

Vice Presidents

3 members

Similar companies

Elicio Therapeutics

1 follower

Artiva Biotherapeutics

1 follower

ByHeart

2 followers

Cytokinetics

11 followers

Capricor Therapeutics

1 follower

Neurocrine Biosciences

5 followers

Coherus BioSciences

5 followers

4D Molecular Therapeutics

3 followers

KIA

2 followers

The Cumulus Coffee Company

2 followers

Axsome Therapeutics

2 followers

Explore companies